2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-164580
    RO3244794 361457-01-4 99.64%
    RO3244794 is a potent and selective IP (prostacyclin) receptor antagonist, with a pKi of 7.7 and 6.9 in human platelet and recombinant IP receptor system, respectively. RO3244794 exhibits analgesic and anti-inflammatory potential.
    RO3244794
  • HY-164927
    AV5124 2417851-93-3 99.11%
    AV5124, a prodrug of AV5116, is an orally active influenza virus cap-dependent endonuclease (CEN) endonuclease inhibitor.
    AV5124
  • HY-165613
    Pam2Cys 656831-18-4 99.82%
    Pam2Cys (Dipalmitoyl-S-glyceryl-cysteine; S-[2,3-Bis(palmitoyloxy)propyl]cysteine) is a TLR2 agonist and immunostimulant. Pam2Cys binds to TLR2 to activate dendritic cells and trigger the TLR2-dependent NF-κB signaling pathway. Pam2Cys also induces dendritic cell maturation by upregulating the expression of cell surface MHC II molecules. Pam2Cys activates innate immune signaling pathways, drives pro-inflammatory and antimicrobial responses, enhances the expression of macrophage activation markers, increases phagocytic activity, induces the release of IL-12 and pro-inflammatory cytokines, and polarizes macrophages into a pro-inflammatory, antimicrobial phenotype without interfering with IL-10-induced macrophage polarization. Pam2Cys also serves as the lipid moiety in synthetic lipopeptide vaccines and possesses self-adjuvant properties. Pam2Cys enhances the immunogenicity of conjugated peptide segments and induces cellular and humoral immune responses. However, it does not activate CD4 T cells in mouse splenocyte cultures when used alone. Pam2Cys activates pulmonary TLR2 signaling pathways, triggers innate immune responses, recruits neutrophils and macrophages, induces the secretion of various cytokines, alleviates symptoms and damages associated with influenza A virus infection in mice without impairing adaptive immunity. Pam2Cys can be used in studies related to tuberculosis and influenza A virus infection.
    Pam2Cys
  • HY-167208
    SR-302 2771319-74-3 98.51%
    SR-302, a chemical probe, is a potent and selectivity DDR/p38 inhibitor, with IC50 values of 0.125, 0.023 and 0.018 μM for p38α, DDR1 and DDR2, respectively. SR-302 can be used for the research of fibrotic disorders, such as renal and pulmonary fibrosis, atherosclerosis, and various forms of cancer.
    SR-302
  • HY-167673
    RNF5-IN-1 1807639-36-6 98.52%
    RNF5-IN-1 (FX12) is a selective RNF5 degrader. RNF5-IN-1 binds to RNF5 and inhibits its E3 activity, and promotes proteasomal degradation of RNF5 in an endoplasmic reticulum (ER)-associated degradation (ERAD) way in cells. RNF5-IN-1 inhibits α-1-antitrypsin (NHK) dislocation with an IC50 value of 2.7 μM. RNF5-IN-1 can be used for research of cystic fibrosis, acute myeloid leukemia, and certain viral infections.
    RNF5-IN-1
  • HY-168328
    FKK6 2238839-34-2 99.14%
    FKK6 is a selective agonist for pregnane X receptor (PXR) with an EC50 of 1.2 µM. FKK6 exhibits good affinity with plasma proteins, and good metabolic metabolism in human microsomes. FKK6 inhibits PXR-related NF-κB signaling pathway, inhibits the expression of inflammatory factors, and exhibits anti-inflammatory activity against DSS (HY-116282)-induced colitis in mouse model.
    FKK6
  • HY-168624
    VAV1 degrader-2 3050683-29-6 98.15%
    VAV1 degrader-2 is a molecular glue degrader based on targeting Vav guanine nucleotide exchange factor 1 (VAV 1) with a DC50 of 4.41 nM. VAV1 degrader-2 can be used in the study of inflammatory and autoimmune diseases.
    VAV1 degrader-2
  • HY-168906
    BI-113823 1119282-90-4 99.23%
    BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension.
    BI-113823
  • HY-169915
    ERAP1 modulator-2 2643320-62-9 98.93%
    ERAP1 modulator-2 (compound 10) is a potent ERAP1 inhibitor with an IC50 value of <100 nM.
    ERAP1 modulator-2
  • HY-170331
    IFNα-IN-1 2700322-66-1 99.95%
    IFNα-IN-1 (AJ2-18) is a IFNα inhibitor that inhibits IFN-α production. IFNα-IN-1 can be used for research of inflammation.
    IFNα-IN-1
  • HY-170949
    STING-IN-11 2925028-15-3 98.65%
    STING-IN-11 (Compound 42) is an orally active STING inhibitor with an IC50 of 37.8 nM. STING-IN-11 can block the palmitoylation of the STING protein and STING downstream signaling, and inhibit STING-mediated inflammation. STING-IN-11 has good in vivo safety and can be used for the research of STING-related inflammatory and autoimmune diseases.
    STING-IN-11
  • HY-172590
    LZ-07 98.27%
    LZ-07 is a IRAK4 PROTAC degrader (DC50 = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593).
    LZ-07
  • HY-172660
    36R-D481 98%
    36R-D481 is a competitive and orthosteric antagonist of IL-36R, effectively inhibiting IL-36 signaling. 36R-D481 can inhibit IL-36α and IL-36γ but not IL-36β induced IL-8 release.
    36R-D481
  • HY-172920
    Wnt/β-catenin-IN-6 98.34%
    Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research.
    Wnt/β-catenin-IN-6
  • HY-173463
    Sirtuin modulator 8 925437-38-3
    Sirtuin modulator 8 is a sirtuin modulator that can activate Sirtuin activity. Sirtuin modulator 8 significantly downregulates the expression of monocyte chemoattractant protein-1 (MCP-1) and upregulates the expression of fibroblast growth factor 21 (FGF21). Sirtuin modulator 8 regulates the expression of inflammation- and metabolism-related genes, showing potential for studying metabolic diseases (such as diabetes, obesity) and inflammatory diseases.
    Sirtuin modulator 8
  • HY-174140
    VU0514009 932973-77-8 99.53%
    VU0514009 is a competitive chemokine-like receptor 1 (CMKLR1) antagonist (EC50=2 nM). VU0514009 prevents chemerin-9-induced arrestin recruitment and receptor internalization, significantly reducing Ca2+ flux response in HEK293 cells. VU0514009 is promising for research of inflammatory diseases and metabolic syndrome.
    VU0514009
  • HY-174156
    Y2641 3092616-03-7 98.31%
    Y2641, a etrahydro-β-carboline derivative, is an orally active dual RANKL/TNF-α inhibitor with Kd values of 3.984 μM and 18.59 μM for RANKL and TNF-α, respectively. Y2641 inhibits RANKL-induced osteoclastogenic and has anti-inflammatory and cartilage destruction. Y2641 can be used for study of osteoarthritis.
    Y2641
  • HY-174979
    Dac590 3084407-00-8
    Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC50 of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML.
    Dac590
  • HY-176180
    PROTAC STING degrader-4 98.25%
    PROTAC STING degrader-4 is a nitro-free covalent STING PROTAC degrader with a DC50 of 3.23 μM. PROTAC STING degrader-4 effectively inhibits STING as well as its downstream signaling, such as p-TBK1 and p-NF-κB (p-P65), and immune-inflammatory cytokines. PROTAC STING degrader-4 mitigates kidney and blood inflammation in Cisplatin (HY-17394)-induced acute kidney injury (AKI) mice model. Pink: STING ligand (HY-176183); Blue: CRBN ligase ligand (HY-103596); Black: linker (HY-176182); CRBN ligase ligand + linker: HY-176181
    PROTAC STING degrader-4
  • HY-17635S
    Leniolisib-d5 98.78%
    Leniolisib-d5 is a deuterated labeled Leniolisib. Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.
    Leniolisib-d5
Cat. No. Product Name / Synonyms Application Reactivity